90 related articles for article (PubMed ID: 16133793)
1. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists.
Benbrook DM; Kamelle SA; Guruswamy SB; Lightfoot SA; Rutledge TL; Gould NS; Hannafon BN; Dunn ST; Berlin KD
Invest New Drugs; 2005 Oct; 23(5):417-28. PubMed ID: 16133793
[TBL] [Abstract][Full Text] [Related]
2. Inverse agonists of retinoic acid receptor/retinoid X receptor signaling as lineage-specific antitumor agents against human adenoid cystic carcinoma.
Viragova S; Aparicio L; Palmerini P; Zhao J; Valencia Salazar LE; Schurer A; Dhuri A; Sahoo D; Moskaluk CA; Rabadan R; Dalerba P
J Natl Cancer Inst; 2023 Jul; 115(7):838-852. PubMed ID: 37040084
[TBL] [Abstract][Full Text] [Related]
3. To flex or not to flex: Oesophageal Soft food bolus obstruction in the modern age.
Moen CM; Tailor H; Hammond S; Hay B; Peedika N; McMurran AL; Choo XY; Stewart M
J Laryngol Otol; 2024 Apr; ():1-19. PubMed ID: 38686530
[No Abstract] [Full Text] [Related]
4. Manipulation of metabolic responses enhances SHetA2 efficacy without toxicity in cervical cancer cell lines and xenografts.
Rai R; Lightfoot S; Benbrook DM
Gynecol Oncol; 2024 Jan; 180():44-54. PubMed ID: 38052108
[TBL] [Abstract][Full Text] [Related]
5. Distinct mechanism of cervical cancer cell death caused by the investigational new drug SHetA2.
Rai R; Chandra V; Kennedy AL; Zuna RE; Benbrook DM
Front Oncol; 2022; 12():958536. PubMed ID: 36203464
[TBL] [Abstract][Full Text] [Related]
6. SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention.
Benbrook DM
Front Cell Dev Biol; 2022; 10():848682. PubMed ID: 35281109
[TBL] [Abstract][Full Text] [Related]
7. Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer.
Chandra V; Rai R; Benbrook DM
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34066052
[TBL] [Abstract][Full Text] [Related]
8. Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile.
Mahjabeen S; Hatipoglu MK; Kosanke SD; Garcia-Contreras D; Benbrook DM; Garcia-Contreras L
J Pharm Sci; 2020 Jun; 109(6):2000-2008. PubMed ID: 32113976
[TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice.
Sharma A; Li M; Thavathiru E; Ibrahim M; Garcia-Contreras L; Benbrook DM; Woo S
AAPS J; 2020 Feb; 22(2):51. PubMed ID: 32086622
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice.
Mahjabeen S; Hatipoglu MK; Benbrook DM; Garcia-Contreras L
J Pharm Sci; 2018 Dec; 107(12):3179-3186. PubMed ID: 30196041
[TBL] [Abstract][Full Text] [Related]
11. Bioanalytical method development and validation of HPLCUV assay for the quantification of SHetA2 in mouse and human plasma: Application to pharmacokinetics study.
Sharma A; Thavathiru E; Benbrook DM; Woo S
J Pharm Technol Drug Res; 2017; 6():. PubMed ID: 29708233
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2.
Sharma A; Benbrook DM; Woo S
PLoS One; 2018; 13(4):e0194046. PubMed ID: 29634717
[TBL] [Abstract][Full Text] [Related]
13. Development of a dietary formulation of the SHetA2 chemoprevention drug for mice.
Benbrook DM; Janakiram NB; Chandra V; Pathuri G; Madka V; Stratton NC; Masamha CP; Farnsworth CN; Garcia-Contreras L; Hatipoglu MK; Lighfoot S; Rao CV
Invest New Drugs; 2018 Aug; 36(4):561-570. PubMed ID: 29273857
[TBL] [Abstract][Full Text] [Related]
14. Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia.
Mahjabeen S; Hatipoglu MK; Chandra V; Benbrook DM; Garcia-Contreras L
J Pharm Sci; 2018 Feb; 107(2):638-646. PubMed ID: 28989018
[TBL] [Abstract][Full Text] [Related]
15. Role of adaptor protein p66Shc in renal pathologies.
Wright KD; Staruschenko A; Sorokin A
Am J Physiol Renal Physiol; 2018 Feb; 314(2):F143-F153. PubMed ID: 28978535
[TBL] [Abstract][Full Text] [Related]
16. SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres.
Benbrook DM; Nammalwar B; Long A; Matsumoto H; Singh A; Bunce RA; Berlin KD
Invest New Drugs; 2014 Jun; 32(3):412-23. PubMed ID: 24254390
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity.
Benbrook DM; Guruswamy S; Wang Y; Sun Z; Mohammed A; Zhang Y; Li Q; Rao CV
Cancer Prev Res (Phila); 2013 Sep; 6(9):908-16. PubMed ID: 23852423
[TBL] [Abstract][Full Text] [Related]
18. Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen.
Doppalapudi RS; Riccio ES; Davis Z; Menda S; Wang A; Du N; Green C; Kopelovich L; Rao CV; Benbrook DM; Kapetanovic IM
Mutat Res; 2012 Jul; 746(1):78-88. PubMed ID: 22498038
[TBL] [Abstract][Full Text] [Related]
19. NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis.
Chengedza S; Benbrook DM
Anticancer Drugs; 2010 Mar; 21(3):297-305. PubMed ID: 20032777
[TBL] [Abstract][Full Text] [Related]
20. Sensitivities of Uterine Adenocarcinoma, Mixed Mullerian Tumor (MMT) and Sarcoma Cell Lines to Chemotherapeutic Agents and a Flex-Het Drug.
Hyde J; Benbrook DM
Am J Pharmacol Toxicol; 2006 Jan; 1(4):83-86. PubMed ID: 19890461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
